Research programme: parathyroid hormone analogues - Chugai

Drug Profile

Research programme: parathyroid hormone analogues - Chugai

Alternative Names: SP-PTH

Latest Information Update: 03 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Pharmaceutical
  • Class Peptide hormones
  • Mechanism of Action Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypoparathyroidism

Most Recent Events

  • 16 Sep 2016 Pharmacodynamics data from a preclinical trial presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hypoparathyroidism in Japan (SC, Injection)
  • 07 Oct 2008 Preclinical trials in Hypoparathyroidism in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top